Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Common Equity: 2010-2025

Historic Common Equity for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $146.8 million.

  • Anika Therapeutics' Common Equity fell 18.38% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 18.38%. This contributed to the annual value of $154.0 million for FY2024, which is 27.45% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Common Equity is $146.8 million, which was down 0.59% from $147.7 million recorded in Q2 2025.
  • Anika Therapeutics' Common Equity's 5-year high stood at $290.1 million during Q3 2021, with a 5-year trough of $146.8 million in Q3 2025.
  • Its 3-year average for Common Equity is $202.7 million, with a median of $208.5 million in 2024.
  • In the last 5 years, Anika Therapeutics' Common Equity grew by 5.39% in 2021 and then plummeted by 33.50% in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Common Equity stood at $287.1 million in 2021, then declined by 0.53% to $285.6 million in 2022, then decreased by 25.67% to $212.3 million in 2023, then decreased by 27.45% to $154.0 million in 2024, then fell by 18.38% to $146.8 million in 2025.
  • Its Common Equity stands at $146.8 million for Q3 2025, versus $147.7 million for Q2 2025 and $148.4 million for Q1 2025.